SOHO 2025 | Diagnostic advances that could further individualize care in ALL
In this video, Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, briefly comments on the potential future advances in diagnostic tools for acute lymphoblastic leukemia (ALL) that could further individualize care for patients with this disease. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think many of us right now are still using RNA and DNA based fusion panels and DNA based next-generation sequencing. These are inherently biased, they’re very helpful, and they can help us to identify most of our patients. But I think once we are better able to develop clinical RNA sequencing, or perhaps even whole-genome sequencing, that is more rapidly interpretable and available for patients more broadly and also more cost-effective, I think this will be the next frontier and a game changer for our patients...
So I think many of us right now are still using RNA and DNA based fusion panels and DNA based next-generation sequencing. These are inherently biased, they’re very helpful, and they can help us to identify most of our patients. But I think once we are better able to develop clinical RNA sequencing, or perhaps even whole-genome sequencing, that is more rapidly interpretable and available for patients more broadly and also more cost-effective, I think this will be the next frontier and a game changer for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
